StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3047% below fair value
$2.88−0.15 (-4.95%)

Close on Nov 17, 2026Market cap $232.05MP/E 12.5Yield –

Protalix BioTherapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Protalix BioTherapeutics's revenue for the twelve months ending Jun 30, 2026 was $80.62M, up 30.1% year over year. For fiscal 2025 it was $52.74M, down 1.2% from the year before. Over ten years it grew 28.3% a year on average. The highest annual figure on record is $65.49M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$52.74M-1.2%
FY2024Dec 31, 2024$53.40M-18.5%
FY2023Dec 31, 2023$65.49M+37.5%
FY2022Dec 31, 2022$47.64M+24.2%
FY2021Dec 31, 2021$38.35M-39.0%
FY2020Dec 31, 2020$62.90M+15.0%
FY2019Dec 31, 2019$54.69M+59.7%
FY2018Dec 31, 2018$34.24M+62.4%
FY2017Dec 31, 2017$21.08M+129.1%
FY2016Dec 31, 2016$9.20M+110.8%
FY2015Dec 31, 2015$4.36M+23.9%
FY2014Dec 31, 2014$3.52M–
FY2013Dec 31, 2013$0-100.0%
FY2012Dec 31, 2012$34.87M+315.8%
FY2011Dec 31, 2011$8.39M+26.3%
FY2010Dec 31, 2010$6.64M+1611.9%
FY2009Dec 31, 2009$388.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$19.90M+27.1%
Q1 FY2026Mar 31, 2026$33.75M+233.7%
Q4 FY2025Dec 31, 2025$9.12M-49.9%
Q3 FY2025Sep 30, 2025$17.85M-0.6%
Q2 FY2025Jun 30, 2025$15.66M+16.2%
Q1 FY2025Mar 31, 2025$10.11M+169.8%
Q4 FY2024Dec 31, 2024$18.22M+73.7%
Q3 FY2024Sep 30, 2024$17.96M+73.6%
Q2 FY2024Jun 30, 2024$13.47M-61.6%
Q1 FY2024Mar 31, 2024$3.75M-60.9%
Q4 FY2023Dec 31, 2023$10.49M+21.7%
Q3 FY2023Sep 30, 2023$10.35M-27.1%
Q2 FY2023Jun 30, 2023$35.08M+300.7%
Q1 FY2023Mar 31, 2023$9.59M-40.4%
Q4 FY2022Dec 31, 2022$8.62M+0.8%
Q3 FY2022Sep 30, 2022$14.18M+17.7%
Q2 FY2022Jun 30, 2022$8.75M+36.2%
Q1 FY2022Mar 31, 2022$16.09M+42.1%
Q4 FY2021Dec 31, 2021$8.55M-56.1%
Q3 FY2021Sep 30, 2021$12.05M-44.3%
Q2 FY2021Jun 30, 2021$6.43M-63.8%
Q1 FY2021Mar 31, 2021$11.32M-20.6%
Q4 FY2020Dec 31, 2020$19.50M+59.2%
Q1 FY2020Mar 31, 2020$21.65M+107.4%
Q4 FY2019Dec 31, 2019$17.76M-34.3%
Q3 FY2019Sep 30, 2019$14.25M+2049.0%
Q2 FY2019Jun 30, 2019$12.25M+510.5%
Q1 FY2019Mar 31, 2019$10.44M+129.3%
Q4 FY2018Dec 31, 2018$27.02M+527.6%
Q3 FY2018Sep 30, 2018$663.00K-91.2%
Q2 FY2018Jun 30, 2018$2.01M-68.4%
Q1 FY2018Mar 31, 2018$4.55M+57.6%
Q4 FY2017Dec 31, 2017$4.31M+106.9%
Q3 FY2017Sep 30, 2017$7.53M+61.2%
Q2 FY2017Jun 30, 2017$6.36M+259.4%
Q1 FY2017Mar 31, 2017$2.89M–
Q4 FY2016Dec 31, 2016$2.08M–
Q3 FY2016Sep 30, 2016$4.67M–
Q2 FY2016Jun 30, 2016$1.77M–

More Protalix BioTherapeutics figures

See a number that looks wrong?